^
    Back
    Association details:
    Biomarker:MYH4 Q1210fs
    Cancer:Esophageal Squamous Cell Carcinoma
    Drug:cisplatin (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2021
    Title:

    610 - Paired alterations of 35-gene expressing profiles before and after neoadjuvant chemoradiation in esophageal squamous cell carcinoma patients impact clinical prognosis

    Published date:
    03/10/2021
    Excerpt:
    A total number of 50 patients with Esophageal squamous cell carcinoma (ESCC) received neoadjuvant CCRT...All patients underwent CCRT using the intensity-modulated radiation therapy in 24 fractions and received concurrent chemotherapy with cisplatin….Mutation of MYH4 (p.Gln1210fs) and TTN (p.Asp7145His) were demonstrated with favorable and unfavorable impact on rate of pathological complete remission, respectively.
    Secondary therapy:
    Chemotherapy